{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000071","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.690624+00:00","generated_at":"2026-05-30T00:15:39.239079+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Curis Q3 net loss narrows to $10.1M; emavusertib shows durable responses in BTKi-progressed PCNSL","bullets":["Net loss of $10.1M ($1.70 per share) vs $12.2M ($2.13) in Q3 2023; nine-month net loss $33.8M.","Revenue $2.9M from Erivedge royalties, essentially flat YoY.","Cash $31.6M after $10.8M October offering; expects runway into mid-2025.","Emavusertib in PCNSL: 3 CR + 1 CRu + 2 PR among 10 BTKi-progressed patients; 3 responses >6 months.","Oral and poster presentations on emavusertib in AML/MDS at ASH in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000071","json":"https://secwatch.observer/filing/0001108205-24-000071.json","markdown":"https://secwatch.observer/filing/0001108205-24-000071.md","text":"https://secwatch.observer/filing/0001108205-24-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000071/0001108205-24-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000071/cris-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:15:39.239079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}